A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression Authors: Ngo Cheung Published: 2026 ABSTRACT AbstractTreatment-resistant depression (TRD) is commonly operationalized as non-remission after at least two adequately delivered antidepressant trials, but the biological heterogeneity of this population remains substantial. This article presents a translational hypothesis and drug-development framework; it reports no original clinical or laboratory data and is not a systematic review. The central hypothesis is that an oral dextromethorphan–CYP2D6-inhibitor–piracetam regimen could, if pharmacokinetically and clinically validated, initiate glutamatergic plasticity, whereas nicotinamide mononucleotide (NMN) plus N-acetylcysteine (NAC), followed only at a later stage by a candidate senescence-directed agent, could be evaluated for effects on the redox, bioenergetic, inflammatory, and cellular-aging context associated with response durability in a biomarker-enriched subset of unipolar TRD. The core regimen is defined as dextromethorphan, one prespecified CYP2D6 inhibitor, and piracetam. Glutamine is retained only as an optional exploratory component and is not part of the core or augmentation definition used for future testing. Existing evidence is uneven. Human studies establish that CYP2D6 phenotype and inhibition materially alter dextromethorphan exposure; NAC has heterogeneous adjunctive psychiatric evidence; NMN has human NAD-related target-engagement data without established antidepressant efficacy; and senolytics have limited early human data outside TRD. Dasatinib plus quercetin is therefore positioned as a later-stage, specialist-supervised research probe rather than a routine psychiatric augmentation. No clinical role can yet be assigned to any proposed combination, and none should be used outside formal research protocols. The proposed development sequence prioritizes pharmacokinetic characterization, safety, target engagement, biomarker-defined subgroup selection, controlled efficacy testing, and independent replication. Introduction Major depressive disorder remains difficult to treat when symptoms persist after standard interventions. In this paper, treatment-resistant depression is used as a research construct referring primarily to adults with current unipolar major depressive disorder who have failed to remit after at least two adequately delivered antidepressant trials of different pharmacological classes, with attention to diagnostic accuracy, adherence, treatment duration, and treatment intensity. This operational definition is consistent with commonly used research criteria, although no single definition has achieved universal acceptance.1–3 Bipolar depression is excluded from the primary target population of the proposed framework because mood activation, antidepressant-associated switching, and the interpretation of glutamatergic response require a separate development pathway. This article is a translational hypothesis paper. It presents no original clinical or laboratory data and is not a systematic review or meta-analysis. Its supporting literature includes independent peer-reviewed studies, regulatory prescribing information, selected preclinical studies, and a limited number of author-authored preprints and clinical observations. Author-authored preprints are treated as hypothesis-generating only and are not used as confirmatory evidence. The article is not clinical guidance, and none of the proposed combinations should be used outside a formal research protocol approved by the relevant ethics, regulatory, pharmacy, and safety-monitoring bodies. Ketamine and esketamine have changed the treatment landscape by demonstrating that clinically meaningful antidepressant effects can occur through mechanisms that differ from the slower monoaminergic pathways emphasized in conventional antidepressant development. The rapid antidepressant literature has implicated NMDA receptor modulation, AMPA throughput, mTOR signaling, BDNF-related plasticity, and synaptic remodeling.4–7 Esketamine and ketamine, however, remain constrained by administration requirements, monitoring burden, cost, access, dissociation, misuse concerns, and uncertainty about how best to sustain acute gains over time.8,9 Dextromethorphan has attracted interest because it is orally available and has NMDA-antagonist and sigma-1-receptor pharmacology. Its disposition is strongly influenced by CYP2D6 phenotype and by coadministration of CYP2D6 inhibitors. Human pharmacokinetic studies show marked differences in dextromethorphan exposure between CYP2D6 phenotypes and after quinidine inhibition.10,11 Additional studies of dextromethorphan–quinidine combinations demonstrate that CYP2D6 inhibition can substantially increase and prolong dextromethorphan exposure.12 These pharmacokinetic observations are directly relevant to any attempt to evaluate dextromethorphan as an oral plasticity-oriented intervention. Dextromethorphan-containing products have also established two distinct clinical facts. First, dextromethorphan–quinidine is an approved pharmacotherapy for pseudobulbar affect in which quinidine is used primarily to inhibit CYP2D6 and alter dextromethorphan exposure.13 Second, dextromethorphan–bupropion is an approved antidepressant combination for adults with major depressive disorder.14 Neither fact validates other dextromethorphan combinations, piracetam augmentation, or treatment of TRD with an untested multi-drug regimen. Bupropion, quinidine, fluoxetine, paroxetine, and other CYP2D6 inhibitors are pharmacologically non-interchangeable and carry different effects on seizure threshold, blood pressure, QTc, serotonin toxicity, drug interactions, and intrinsic antidepressant activity. A prior author-authored hypothesis paper proposed an oral combination of dextromethorphan, a CYP2D6-inhibiting antidepressant, piracetam, and glutamine as a possible ketamine-class strategy.15 That article was a mechanistic proposal and did not constitute a controlled clinical evaluation of the complete combination. The present framework therefore uses the neutral term “proposed oral glutamatergic regimen” and defines the core regimen as dextromethorphan, one prespecified CYP2D6 inhibitor, and piracetam. Glutamine is retained only as an optional exploratory component. It is not part of the core definition and is not included in the primary NMN-plus-NAC augmentation arm. A second issue is durability. Rapidly opening a plasticity window may not be sufficient if the cellular environment does not support consolidation. Independent studies have associated major depression and late-life depression with molecular senescence markers and SASP-related biology, although these findings remain correlational and do not establish that senescence causes depression or that senolytic treatment improves depressive symptoms.16–18 Cellular senescence may act as a protective tumor-suppressive program in some contexts while also contributing to chronic inflammatory signaling through the SASP.19,20 Inflammation and immune-metabolic activation are also implicated in depression biology, but their causal and therapeutic significance varies across patients.21,22 The bioenergetic component of the hypothesis is similarly provisional. Human studies have reported altered mitochondrial function, oxidative stress, or mitochondrial respiratory markers in some depression cohorts, while other studies have failed to distinguish patients with major depression from controls on selected mitochondrial measures.23–25 This inconsistency argues against treating mitochondrial or NAD-related markers as established diagnostic or treatment-selection biomarkers. It does, however, provide a rationale for studying whether bioenergetic measures modify response durability or identify a subgroup in which cellular stress constrains plasticity. NAD+ is relevant to this framework because it participates in mitochondrial metabolism, DNA repair, sirtuin activity, and cellular stress responses.26,27 Human NMN studies have examined NAD-related biomarkers, tolerability, metabolic measures, or physical function, but they have not established antidepressant efficacy. The proposed role of NMN is therefore target engagement and mechanistic testing rather than treatment of depression. The author’s prior work has proposed a pruning–plasticity model of depression, computationally examined network fragility and consolidation, and linked symptom-level treatment outcomes to bioenergetic and NAD-related pathways.28–30 Those publications are hypothesis-generating and are not necessary prerequisites for the present proposal. The genuinely new element here is the staged translational structure: the core oral regimen is separated from the senescence-modulating augmentation arm; the eponymous label is removed; glutamine is made optional rather than definitional; human evidence is mapped by component; and the development sequence is explicitly sequential, pharmacokinetic, safety-led, and falsifiable. Methods: Evidence-Synthesis Approach A targeted, non-systematic evidence search was undertaken for this conceptual paper and completed on 3 August 2026. Searches were conducted in PubMed/MEDLINE and supplemented with searches of Embase, PsycINFO, the Cochrane Library, publisher websites, regulatory databases, and citation lists of key papers. Search terms combined the following concepts: “treatment-resistant depression”, “major depressive disorder”, “ketamine”, “esketamine”, “dextromethorphan”, “CYP2D6”, “quinidine”, “bupropion”, “fluoxetine”, “paroxetine”, “piracetam”, “N-acetylcysteine”, “glutathione”, “nicotinamide mononucleotide”, “NAD”, “mitochondria”, “cellular senescence”, “SASP”, “senolytic”, “fisetin”, “dasatinib”, and “quercetin”. Eligible material included peer-reviewed human studies of pharmacokinetics, safety, target engagement, or psychiatric outcomes; key preclinical mechanistic studies; regulatory prescribing information; and selected preprints directly relevant to the author’s conceptual model. Peer-reviewed human studies were prioritized for claims about clinical effects, safety, and feasibility. Preprints were identified separately and treated as hypothesis-generating. Author-authored papers, preprints, and case reports were not used as confirmatory evidence and were considered alongside, rather than in place of, independent literature. No formal systematic-review protocol, risk-of-bias assessment, quantitative synthesis, or meta-analysis was performed. The categories used in Table 1 are qualitative rather than validated evidence grades. “Established pharmacokinetic evidence” refers to reproducible human pharmacokinetic findings without implying therapeutic efficacy. “Moderate” indicates more than one human study or a combination of human and convergent mechanistic evidence, with important limitations. “Low” indicates limited, heterogeneous, indirect, or non-specific clinical evidence. “Early or limited” indicates small exploratory human studies, preclinical evidence, or both. “Absent” indicates that no direct clinical evidence for TRD or the proposed combination was identified. “Hypothetical” indicates an inference from adjacent mechanisms without direct testing of the proposed causal chain. Table 1Qualitative Evidence Map for the Proposed FrameworkClaim or ComponentEvidence CategoryInterpretationCYP2D6 inhibition changes dextromethorphan exposureEstablished pharmacokinetic evidenceHuman studies consistently show that CYP2D6 phenotype and inhibition alter dextromethorphan disposition. This supports pharmacokinetic investigation but not antidepressant efficacy.10–14The proposed oral glutamatergic regimen improves TRDAbsent direct efficacy evidenceThe complete regimen has not been tested in a controlled clinical trial in unipolar TRD. The prior hypothesis paper was mechanistic and did not establish efficacy.15Piracetam provides antidepressant or AMPA-directed benefit in the proposed regimenLow and indirectA small human study examined piracetam in patients receiving ECT but did not establish a regimen-specific antidepressant effect.31NAC affects glutathione, oxidative stress, and glutamate-regulatory systemsModerate mechanistic evidenceBiochemical and psychiatric literature supports redox and glutamate-related activity, but the clinical meaning of these effects varies across populations.32–34NAC improves depressive symptomsLow-to-moderate, heterogeneousRandomized and meta-analytic findings suggest possible adjunctive benefit, but the principal MDD trial was not unequivocally positive at its primary endpoint and evidence is not specific to the proposed regimen.33,34NMN changes NAD-related biomarkers in humansModerate target-engagement evidenceHuman studies in generally healthy participants report changes in NAD-related measures and short-term tolerability.35–37NMN improves depression in humansAbsent direct evidenceNo controlled human study establishes NMN as an antidepressant or TRD augmentation. Existing mood-related findings are primarily preclinical.38–40Senotherapeutic agents reduce senescence-related markers in humansEarly or limitedSmall studies outside TRD have reported feasibility, pharmacokinetic, biomarker, or exploratory functional findings.41–43Senotherapeutic agents improve TRDAbsentNo direct clinical evidence supports senolytics as antidepressant treatment or TRD augmentation.NMN, NAC, and a senescence-directed agent improve the durability of the proposed oral glutamatergic regimenHypotheticalThe combination is inferred from adjacent mechanisms and remains untested. Peripheral biomarker changes would not by themselves establish central synaptic repair.15,28–30 Table 1Qualitative Evidence Map for the Proposed FrameworkClaim or ComponentEvidence CategoryInterpretationCYP2D6 inhibition changes dextromethorphan exposureEstablished pharmacokinetic evidenceHuman studies consistently show that CYP2D6 phenotype and inhibition alter dextromethorphan disposition. This supports pharmacokinetic investigation but not antidepressant efficacy.10–14The proposed oral glutamatergic regimen improves TRDAbsent direct efficacy evidenceThe complete regimen has not been tested in a controlled clinical trial in unipolar TRD. The prior hypothesis paper was mechanistic and did not establish efficacy.15Piracetam provides antidepressant or AMPA-directed benefit in the proposed regimenLow and indirectA small human study examined piracetam in patients receiving ECT but did not establish a regimen-specific antidepressant effect.31NAC affects glutathione, oxidative stress, and glutamate-regulatory systemsModerate mechanistic evidenceBiochemical and psychiatric literature supports redox and glutamate-related activity, but the clinical meaning of these effects varies across populations.32–34NAC improves depressive symptomsLow-to-moderate, heterogeneousRandomized and meta-analytic findings suggest possible adjunctive benefit, but the principal MDD trial was not unequivocally positive at its primary endpoint and evidence is not specific to the proposed regimen.33,34NMN changes NAD-related biomarkers in humansModerate target-engagement evidenceHuman studies in generally healthy participants report changes in NAD-related measures and short-term tolerability.35–37NMN improves depression in humansAbsent direct evidenceNo controlled human study establishes NMN as an antidepressant or TRD augmentation. Existing mood-related findings are primarily preclinical.38–40Senotherapeutic agents reduce senescence-related markers in humansEarly or limitedSmall studies outside TRD have reported feasibility, pharmacokinetic, biomarker, or exploratory functional findings.41–43Senotherapeutic agents improve TRDAbsentNo direct clinical evidence supports senolytics as antidepressant treatment or TRD augmentation.NMN, NAC, and a senescence-directed agent improve the durability of the proposed oral glutamatergic regimenHypotheticalThe combination is inferred from adjacent mechanisms and remains untested. Peripheral biomarker changes would not by themselves establish central synaptic repair.15,28–30 Qualitative Evidence Map for the Proposed Framework A Drug-Development Frame for the Proposed Oral Regimen The practical appeal of an oral glutamatergic strategy is that it could be easier to study, maintain, and distribute than supervised intravenous or intranasal treatment. That appeal does not reduce the need for formal development. A multi-drug regimen can produce pharmacokinetic interactions, overlapping adverse effects, attribution problems, and misleading signals from concomitant treatment changes. The appropriate question is therefore not whether the proposed oral regimen should be adopted clinically, but whether its component logic is sufficiently defined to justify staged pharmacokinetic and safety studies. The core proposed oral glutamatergic regimen consists of three components: dextromethorphan, one prespecified CYP2D6 inhibitor, and piracetam. The CYP2D6 inhibitor is intentionally not fixed in this conceptual paper because the available candidates are not interchangeable. A future study must prospectively select one inhibitor and one formulation, provide a pharmacological rationale, define the exposure target, specify the dose rationale within the approved research protocol, and include a plan for CYP2D6 phenotyping or genotyping and pharmacokinetic measurement. Quinidine, bupropion, fluoxetine, paroxetine, and other CYP2D6 inhibitors differ in their effects on QTc, seizure threshold, blood pressure, serotonergic burden, CYP-mediated interactions, half-life, and intrinsic antidepressant pharmacology.13,14 Any clinical improvement attributed to the proposed regimen could therefore reflect the independent effect of the inhibitor, an interaction between the inhibitor and background medication, or nonspecific expectancy and regression-to-the-mean effects. A study that does not fix the inhibitor cannot adequately identify the active component. Glutamine is treated as optional and exploratory. It is not part of the core regimen and is not included in the primary augmentation definition. The present augmentation arm is limited to NMN plus NAC, with a candidate senescence-directed agent considered only after the core regimen and the NMN-plus-NAC combination have been separately characterized. This separation is intended to reduce interpretive ambiguity and prevent a large multi-drug stack from being tested before its individual components are understood. Dextromethorphan provides the most clearly defined pharmacokinetic rationale. Its exposure is sensitive to CYP2D6 activity, and the effects of inhibition vary by inhibitor, phenotype, genotype, formulation, and background medication.10–14 That rationale supports a controlled pharmacokinetic study. It does not demonstrate that a particular exposure produces antidepressant efficacy, that the exposure is safe when combined with piracetam, or that a higher or prolonged exposure is preferable to the approved dextromethorphan-containing products. Piracetam is included as a proposed plasticity-supporting component, but its antidepressant evidence is limited. A small randomized study examined piracetam in patients undergoing electroconvulsive treatment for depressive illness or schizophrenia and did not demonstrate a significant effect on ECT-related cognitive disturbance; clinical ratings were not the primary basis for establishing antidepressant efficacy.31 Piracetam should therefore be regarded as an unvalidated component requiring independent pharmacodynamic and safety characterization rather than as an established AMPA-directed antidepressant. NAC occupies a different position. It has a plausible role at the intersection of glutathione synthesis, oxidative stress, cystine–glutamate exchange, and inflammatory signaling.32 Clinical findings have been mixed. In a large randomized study of adjunctive NAC in major depressive disorder, the primary depression outcome did not separate significantly from placebo at the prespecified endpoint, although some later and secondary measures favored NAC.33 An updated meta-analysis reported a modest pooled signal with heterogeneity and wide uncertainty, supporting further investigation but not a regimen-specific efficacy claim.34 NMN is included as a candidate NAD-related target-engagement intervention. Human studies have reported increases in NAD-related measures and have generally focused on healthy participants, short-term tolerability, metabolic outcomes, or physical function.35–37 Preclinical work has reported effects on depression-like behavior or mitochondrial pathways in rodents, but these findings do not establish antidepressant efficacy in humans.38–40 NMN is therefore best positioned as a mechanistic probe whose effect on NAD metabolite profiles, mitochondrial measures, inflammatory markers, and clinical outcomes should be tested prospectively. The senescence-directed component is the most experimental. Fisetin and other non-oncology candidates have been proposed as senotherapeutic agents, but human psychiatric data are absent. Dasatinib plus quercetin has been evaluated in small human studies involving diabetic kidney disease, early Alzheimer’s disease, and older adults with cognitive or mobility impairment.41–43 These studies provide feasibility and target-engagement signals but do not demonstrate benefit in depression or TRD. The central development principle is therefore sequential testing. The core oral glutamatergic regimen should first be pharmacokinetically characterized with one fixed CYP2D6 inhibitor. Only after adequate safety and exposure data should NMN plus NAC be evaluated as an augmentation arm. A senotherapeutic component should be considered only after lower-risk candidates demonstrate acceptable target engagement and tolerability. Dasatinib-containing research should remain a later-stage, specialist-supervised probe under full regulatory, ethics, pharmacy, laboratory, and adverse-event oversight. Pruning, Plasticity, Senescence, and the Current Evidence Gap The proposed model is compatible with a two-stage view of vulnerability. Developmental changes in synaptic connectivity could create a latent circuit-level susceptibility, while later failures of plasticity, energy production, redox control, or inflammatory regulation could influence whether that susceptibility becomes persistent or treatment-resistant. This model is not required to explain all depression and should not be treated as an established etiological account. The author’s prior genetic and computational work has suggested that pruning-related processes may be relevant to the polygenic architecture of major depressive disorder and that network fragility may be partly reversible through simulated reconnection or repeated plasticity windows.28,29 These analyses are inferential and model-dependent. They do not establish that pharmacological plasticity restores synapses in patients, that the proposed oral regimen reproduces ketamine biology, or that senescence is the mechanism governing relapse. The independent depression literature supports a more limited conclusion. Molecular senescence and SASP-associated markers have been observed in some depression cohorts, particularly in later-life depression, but the directionality, specificity, sex moderation, treatment relevance, and relationship to central nervous system biology remain unresolved.16–18 Similarly, mitochondrial studies have reported both abnormalities and null findings, with some evidence that mitochondrial measures may differ between antidepressant responders and nonresponders without distinguishing all patients with depression from healthy controls.23–25 The proposed framework therefore treats senescence, inflammation, mitochondrial function, and NAD metabolism as candidate modifiers rather than established endotypes. A biomarker-enriched subgroup would need to be defined prospectively using validated assays, prespecified thresholds, and replication samples. Symptoms such as fatigue, cognitive difficulty, sleep disturbance, appetite change, and reduced stress tolerance may be clinically useful enrichment variables, but they are not substitutes for validated biological markers. Defining the Proposed Senescence-Modulating Arm The proposed augmentation arm has two initial components and one conditional component: NMN as a candidate NAD-related target-engagement intervention;NAC as a redox- and glutamate-regulatory adjunct; andA candidate senescence-directed agent considered only in a later stage, after adequate safety and target-engagement information has been obtained. NMN as a candidate NAD-related target-engagement intervention; NMN as a candidate NAD-related target-engagement intervention; NAC as a redox- and glutamate-regulatory adjunct; and NAC as a redox- and glutamate-regulatory adjunct; and A candidate senescence-directed agent considered only in a later stage, after adequate safety and target-engagement information has been obtained. A candidate senescence-directed agent considered only in a later stage, after adequate safety and target-engagement information has been obtained. This structure deliberately excludes glutamine from the augmentation definition. Glutamine may be studied separately as an exploratory variable, but combining it with the core and augmentation components before its contribution is known would further increase interpretive and safety complexity (Figure 1). Figure 1Candidate glutamatergic and senescence-modulating framework. (a) The core proposed oral glutamatergic regimen consists of dextromethorphan, one prespecified CYP2D6 inhibitor, and piracetam. The augmentation arm consists initially of NMN plus NAC, with a candidate senescence-directed agent considered only at a later stage. Glutamine is shown outside the core definition as an optional exploratory component. (b) The relationship between NAD-related biology, cellular senescence, SASP signaling, and theoretical oncogenic considerations is presented as a conceptual question rather than a protective mechanism. Dashed arrows indicate hypothesized relationships. The figure does not imply that NMN increases cancer risk, that senolytics prevent cancer, or that combining NMN with a senolytic neutralizes any theoretical liability. No component is presented as a clinical recommendation.Two diagrams show a glutamatergic regimen framework and NAD-related biology with senescence pathways.The first diagram outlines a candidate glutamatergic and senescence-modulating framework. It begins with a core oral glutamatergic regimen consisting of dextromethorphan, a CYP2D6 inhibitor and piracetam. This progresses to an augmentation arm with NMN and NAC, followed by a later-stage component involving a candidate senescence-directed agent. Glutamine is noted as an optional exploratory component outside the core definition. The second diagram illustrates the relationship between NMN, NAD-related biology, cellular senescence and SASP signaling. NMN is shown as an exogenous input to NAD-related biology, which involves mitochondria, sirtuins and repair. The diagram includes hypothesized relationships, such as NAD-related biology modifying cellular senescence, which in turn drives SASP signaling. Feedback and unresolved protective aspects are also indicated. Candidate glutamatergic and senescence-modulating framework. (a) The core proposed oral glutamatergic regimen consists of dextromethorphan, one prespecified CYP2D6 inhibitor, and piracetam. The augmentation arm consists initially of NMN plus NAC, with a candidate senescence-directed agent considered only at a later stage. Glutamine is shown outside the core definition as an optional exploratory component. (b) The relationship between NAD-related biology, cellular senescence, SASP signaling, and theoretical oncogenic considerations is presented as a conceptual question rather than a protective mechanism. Dashed arrows indicate hypothesized relationships. The figure does not imply that NMN increases cancer risk, that senolytics prevent cancer, or that combining NMN with a senolytic neutralizes any theoretical liability. No component is presented as a clinical recommendation. NMN and NAD-Related Biology NAD+ participates in mitochondrial metabolism, DNA repair, sirtuin activity, and cellular stress responses.26,27 These pathways may be relevant to synaptic remodeling because synapse formation, dendritic maintenance, local protein synthesis, and cellular repair require energy and redox control. Human NMN studies have reported changes in blood NAD-related measures and generally short-term tolerability in healthy adults.35–37 The populations studied have not been selected for TRD, inflammatory activation, senescence burden, or low bioenergetic reserve. Preclinical depression-related studies have reported that NMN or related NAD-linked pathways can influence depression-like behavior and mitochondrial measures in rodents.38–40 These results support target engagement and experimental investigation. They do not establish that NMN improves depression in humans, that peripheral NAD-related changes reflect brain changes, or that NMN would improve the durability of a glutamatergic response. NAC and Redox–Glutamate Regulation NAC is a cysteine donor for glutathione synthesis and may influence oxidative stress, inflammatory signaling, and cystine–glutamate exchange.32 Its psychiatric evidence is more developed than that of NMN or senolytics, but it remains heterogeneous. The MDD randomized trial was not unequivocally positive at its primary endpoint,33 while pooled evidence suggests a possible but non-specific adjunctive effect.34 The relevant question for this framework is not whether NAC is broadly antidepressant, but whether it changes a prespecified redox or glutamate-related biomarker and whether such change modifies the durability of response to a fixed oral glutamatergic regimen. Candidate Senescence-Directed Agents Senescence-directed strategies remain biologically heterogeneous. Fisetin has been studied primarily in preclinical and geroscience contexts. Dasatinib plus quercetin has reached small exploratory human studies outside psychiatry, including studies of diabetic kidney disease and cognitive or mobility impairment in older adults.41–43 These studies have not established the optimal biomarker panel, the degree of senescent-cell clearance achieved in humans, or whether peripheral changes reflect relevant changes in the brain. The biological rationale for senolytics must also be balanced against the possibility that senescence has context-dependent protective functions. A treatment that changes senescence markers could have effects unrelated to improved plasticity and could carry tissue-specific risks. Recent preclinical work reporting oligodendrocyte dysfunction and demyelination after dasatinib-plus-quercetin exposure further supports caution in moving from peripheral senescence biology to psychiatric use.44 Mechanistic Rationale for Combining Glutamatergic Plasticity with Senescence Modulation The proposed combination is a conditional mechanistic sequence rather than an established synergistic treatment. The first link is that dextromethorphan, when exposure is altered by a prespecified CYP2D6 inhibitor, could engage NMDA- and sigma-1-related pharmacology. The second link is that piracetam might modify downstream excitatory transmission or plasticity-related signaling. The third link is that NMN, NAC, and a candidate senescence-directed intervention might influence the metabolic, redox, or inflammatory context in which plasticity occurs. Each link requires independent testing. The first candidate interaction concerns plasticity initiation. Ketamine research supports the general principle that NMDA-related pharmacology can produce rapid changes in synaptic signaling and plasticity-related pathways.4–7 Dextromethorphan has different pharmacology, pharmacokinetics, and clinical exposure characteristics. It should not be assumed to reproduce ketamine’s molecular or clinical effects. Likewise, the proposed role of piracetam remains uncertain and should not be described as established AMPA potentiation in humans. The second candidate interaction concerns bioenergetic support. NAD+-dependent processes may influence mitochondrial function, DNA repair, and cellular stress responses.26,27 Mitochondrial abnormalities have been reported in some human depression studies, but peripheral mitochondrial findings are not equivalent to neuronal bioenergetic failure.23–25 NMN could therefore be evaluated as a target-engagement intervention, while clinical effects on fatigue, cognitive function, or mood should remain exploratory. The third candidate interaction concerns redox and glutamate regulation. NAC may influence glutathione availability, oxidative stress, and cystine–glutamate exchange.32 These processes could theoretically alter the tolerability or stability of a plasticity-oriented intervention. However, an improvement in GSH/GSSG ratio or another peripheral redox measure would not demonstrate synaptic repair, central glutamate normalization, or improved remission durability. The fourth candidate interaction concerns inflammatory signaling. Senescent cells can contribute to SASP-related cytokine and protease release, but peripheral SASP markers are not specific measures of senescent-cell burden in the brain. A reduction in a circulating SASP marker could reflect changes in immune activation, medication exposure, metabolism, infection status, or other non-neural processes. The proposed model therefore predicts relationships among biomarkers rather than guaranteed treatment effects. Dashed conceptual pathways in Figure 2 should be interpreted as hypotheses to be tested, not as established mechanisms. Figure 2Hypothesized temporal relationship between oral glutamatergic plasticity and senescence-related biology. (a) The proposed oral glutamatergic regimen is shown as a candidate plasticity-initiation signal, while NMN, NAC, and a later-stage senescence-directed agent are shown as candidate modifiers of the bioenergetic, redox, inflammatory, and cellular-aging context. The figure does not specify an expected onset time, relapse reduction, duration of benefit, or residual-symptom effect. (b) Candidate molecular intersections include NMDA-related signaling, AMPA-related transmission, BDNF and mTOR pathways, NAD-linked metabolism, glutathione biology, cystine–glutamate exchange, and SASP-associated inflammatory signaling. Dashed arrows indicate unverified relationships. Peripheral biomarker movement is not equated with central synaptic repair.Diagram of oral glutamatergic plasticity linked to aging biology with context modifiers.The image consists of two parts. The first part shows a timeline labeled ′Initiation′ with ′Oral Glutamatergic Regimen′ as a candidate plasticity-initiation signal. It includes ′NAC′, ′NMN′ and ′Senescence-Directed Agent′ as context modifiers. The timeline is non-quantitative, indicating progression order only. The second part is a flowchart depicting interactions between ′Glutamatergic Regimen′, ′NMDA signaling′, ′AMPA transmission′, ′BDNF′, ′mTOR pathway′, ′NAD-linked metabolism′, ′Cystine-glutamate exchange′, ′Glutathione biology′ and ′SASP inflammatory signaling′. Dashed arrows indicate unverified relationships and the chart includes notes on receptor engagement and inflammatory feedback. Hypothesized temporal relationship between oral glutamatergic plasticity and senescence-related biology. (a) The proposed oral glutamatergic regimen is shown as a candidate plasticity-initiation signal, while NMN, NAC, and a later-stage senescence-directed agent are shown as candidate modifiers of the bioenergetic, redox, inflammatory, and cellular-aging context. The figure does not specify an expected onset time, relapse reduction, duration of benefit, or residual-symptom effect. (b) Candidate molecular intersections include NMDA-related signaling, AMPA-related transmission, BDNF and mTOR pathways, NAD-linked metabolism, glutathione biology, cystine–glutamate exchange, and SASP-associated inflammatory signaling. Dashed arrows indicate unverified relationships. Peripheral biomarker movement is not equated with central synaptic repair. Peripheral tissues may participate in psychiatric vulnerability through immune, metabolic, and inflammatory signaling. That possibility is compatible with the proposed framework but remains particularly vulnerable to overinterpretation. Peripheral target engagement may be useful for trial development; it cannot by itself establish central senescence reduction, synaptic restoration, or a causal role in depression. Predicted Research Role in Treatment-Resistant Depression No clinical role can yet be assigned to the proposed combination. If future studies support the framework, the most informative use would be as an investigational augmentation strategy in a biologically characterized subgroup rather than as a broad treatment for all patients with TRD. A candidate research population could include adults with unipolar TRD and residual fatigue, cognitive dysfunction, sleep disturbance, metabolic strain, inflammatory activation, or abnormal prespecified bioenergetic or senescence-related markers. These features should be treated as enrichment variables rather than treatment indications. The biomarkers should be measured before treatment, during target-engagement assessment, and during follow-up, with assay reproducibility and analytic validity established before the trial begins. Durability is a logical outcome because the proposed augmentation arm is not expected to function primarily as an acute antidepressant. A suitable development program would therefore include symptom change, functional recovery, cognitive and fatigue measures, relapse, time to relapse, and maintenance of response. At least 6–12 months of follow-up would be needed to evaluate durability, although a small feasibility study could not establish long-term efficacy or uncommon toxicities. Residual symptoms should be treated as secondary exploratory outcomes. Fatigue, reduced cognitive stamina, sleep disturbance, and stress intolerance may overlap with inflammatory and metabolic biology, but symptom improvement could also result from nonspecific mood improvement, expectancy, sleep changes, or concomitant treatment modifications. Any symptom-specific prediction would require prespecified measurement and independent replication. Scope Limitations Bipolar-spectrum illness, traumatic brain injury, Alzheimer’s disease prevention, and amyotrophic lateral sclerosis are outside the primary scope of this paper. They may be relevant to future mechanistic work, but extending the proposed framework across these conditions before unipolar TRD safety and pharmacokinetics are characterized would increase clinical and interpretive uncertainty. The author-authored clinical observations that have been published in related populations should therefore be described accurately. One report involved three consecutive adults with bipolar disorder and obsessive-compulsive symptoms treated in routine practice.45 Another described a longitudinal case of post-traumatic brain injury bipolar-spectrum illness.46 These were uncontrolled observations, did not include randomized comparators, and involved clinically complex populations and concomitant treatment decisions. They cannot establish efficacy in unipolar TRD or validate the proposed mechanism. Safety, Drug-Interaction, and Regulatory Considerations This paper is not clinical guidance. None of the combinations described here should be used outside a formal research protocol. The central safety issue is that the proposed framework combines exposure manipulation with several agents whose individual risks, interactions, and product-quality characteristics differ substantially. Dextromethorphan and CYP2D6 Inhibition Dextromethorphan exposure is influenced by CYP2D6 phenotype, genotype, concomitant inhibition, formulation, and other medicines.10–14 A future study should measure or otherwise characterize exposure rather than infer it from the nominal treatment assignment. Phenotyping or genotyping may help explain variability, but neither replaces clinical monitoring or pharmacokinetic assessment. The main safety domains include serotonergic toxicity, altered mental status, dissociation, sedation, dizziness, misuse potential, mood activation, psychosis, seizure risk, and drug interactions. Quinidine-containing approaches add QTc, thrombocytopenia, hepatic, anticholinergic, and interaction concerns.13 Bupropion-containing approaches add seizure-threshold and blood-pressure considerations and may independently contribute to antidepressant response.14 Fluoxetine, paroxetine, and other antidepressant inhibitors introduce additional serotonergic and pharmacokinetic complexity. The use of a CYP2D6 inhibitor must therefore be treated as an experimental variable rather than as a generic method for increasing dextromethorphan exposure. A valid study should fix the inhibitor, formulation, exposure target, and interaction-management plan before enrollment. Dasatinib-Containing Approaches Dasatinib is an oncology drug, not a nutraceutical or established psychiatric augmentation. The prescribing information identifies clinically significant risks including myelosuppression, bleeding, fluid retention and pleural effusion, cardiovascular toxicity, pulmonary arterial hypertension, QT prolongation, hepatotoxicity, embryo-fetal toxicity, and CYP3A4-related interactions.47 Dasatinib is primarily metabolized by CYP3A4, and strong CYP3A4 inhibition can substantially increase dasatinib exposure.47 Quercetin has shown CYP3A-modulating effects in human probe-drug studies, with the direction and magnitude varying according to dose, duration, formulation, and whether intestinal or hepatic CYP3A activity is assessed.48,49 The quercetin–CYP3A4/dasatinib combination therefore represents a plausible pharmacokinetic concern. At present, no established clinically relevant quercetin–dasatinib interaction has been demonstrated in humans, particularly for the intermittent dosing schedules proposed for senolytic research. Quercetin should not be assumed to be pharmacokinetically neutral. Any dasatinib-plus-quercetin study would require formal pharmacokinetic evaluation of dasatinib and relevant metabolite exposure, review of concomitant CYP3A4 modulators and gastric-acid–reducing agents, specialist oversight, prespecified laboratory and cardiopulmonary monitoring, pregnancy-prevention procedures where relevant, and strict protocol-defined stopping rules. Accordingly, dasatinib plus quercetin should be considered only as a later-stage, specialist-supervised, high-risk research probe. It should not be considered until lower-risk senescence-directed candidates, such as standardized non-oncology candidates, have shown acceptable target engagement and tolerability. Any dasatinib-containing study would require full regulatory and ethics review, oncology or specialist pharmacy input, prespecified laboratory and cardiopulmonary monitoring, pregnancy-prevention procedures where relevant, and strict protocol-defined stopping rules. A theoretical argument that senolytic clearance might counterbalance a possible oncogenic liability of NAD support is not evidence of cancer protection. The relationship among NAD metabolism, senescence, tumor biology, and senolytic exposure is context-dependent and cannot be neutralized by combining agents without direct evidence. NMN and NAC NMN has limited long-term human safety information in psychiatric populations. Human studies have generally involved healthy participants and relatively short follow-up.35–37 NMN is not currently established as a CYP2D6 inhibitor or inducer, and no established clinically relevant human interaction between NMN and CYP2D6, or between NMN and dextromethorphan/dextrorphan exposure, has been demonstrated. However, the available human NMN studies were not designed to assess CYP2D6 activity or dextromethorphan pharmacokinetics.35–37 Any study adding NMN to a dextromethorphan-containing regimen should therefore include formal pharmacokinetic evaluation, ideally measuring dextromethorphan and dextrorphan exposure before and after NMN addition while fixing the CYP2D6 inhibitor, documenting background medications, and accounting for CYP2D6 genotype or phenotype. Until such data are available, NMN should be treated as pharmacokinetically uncharacterized rather than assumed to be neutral. NAC is more familiar in psychiatric research but is not risk-free. Gastrointestinal intolerance, adherence problems, bronchospasm in susceptible individuals, and heterogeneous clinical effects should be anticipated. Its role in the proposed framework is mechanistic and adjunctive rather than established antidepressant treatment. Research Eligibility and Monitoring Domains A formal protocol should prespecify eligibility exclusions and monitoring according to the component being studied. Relevant domains may include pregnancy and breastfeeding, active or recently treated malignancy, unexplained cytopenia, significant bleeding risk, high-risk cardiac disease, prolonged QTc, uncontrolled electrolyte abnormalities, current MAOI exposure, high serotonergic burden, severe hepatic or renal impairment, serious infection, clinically significant immunosuppression, and unstable bipolar-spectrum activation. These are protocol-design considerations, not general clinical instructions. The proposed monitoring domains are summarized in Table 2. A more detailed high-level safety-monitoring framework, including the components to which each domain primarily applies, is provided in Table 3. The safety framework should include medication reconciliation, CYP2D6 and pharmacokinetic assessment, mental-status and mood-activation monitoring, ECG and electrolyte review when indicated, CBC and liver-function assessment for oncology-drug exposure, renal-function assessment, adverse-event adjudication, misuse screening, and product-quality verification. The monitoring plan should be matched to the component under study rather than applied as a generic checklist. Table 2Translational Safety Domains and Monitoring PrioritiesSafety DomainPrincipal ConcernHigh-Level Research ResponseDextromethorphan exposureCYP2D6 phenotype, genotype, inhibitor strength, formulation, and background medication may produce substantial exposure variabilityFix one inhibitor and formulation; characterize pharmacokinetics; predefine exposure targets; perform medication reconciliationSerotonergic and neuropsychiatric effectsSerotonin toxicity, dissociation, sedation, agitation, psychosis, misuse, and mood activationStructured mental-status monitoring; review serotonergic burden; monitor for activation and misuse; define exclusion and stopping procedures prospectivelyCardiac effectsQTc prolongation and interaction-related arrhythmia risk, particularly with quinidine-containing strategiesECG and electrolyte review when indicated; exclude or monitor higher-risk participants according to protocolSeizure and blood-pressure riskRelevant to bupropion-containing strategies and selected background medicinesReview seizure history, blood pressure, interacting drugs, and other threshold-lowering agentsHematologic and bleeding effectsMyelosuppression, thrombocytopenia, bleeding, or platelet dysfunction with oncology-drug exposureCBC, bleeding history, medication review, and specialist oversightHepatic and renal effectsAltered clearance, organ toxicity, or accumulationBaseline and follow-up renal and hepatic assessment; prespecified laboratory monitoringFluid retention and pulmonary toxicityPleural effusion, dyspnea, pulmonary arterial hypertension, or cardiovascular toxicity with dasatinibSpecialist assessment; cardiopulmonary review; symptom-triggered evaluation; strict protocol-defined stopping rulesPregnancy and reproductive safetyEmbryo-fetal toxicity and uncertain reproductive riskPregnancy exclusion or prevention procedures as required by protocol; specialist reviewMalignancy and immune statusUncertainty about long-term NAD modulation and senescence manipulation in active or recent malignancyConservative eligibility criteria; oncology review where relevant; no claim of cancer-risk protectionProduct qualityVariable composition or contamination of non-prescription productsStandardized, analytically characterized products with batch documentation and chain-of-custody procedures Table 3High-Level Safety-Monitoring FrameworkSafety DomainPrincipal ConcernHigh-Level Research ResponseApplies toPharmacokineticCYP2D6 phenotype, genotype, inhibitor strength, formulation, and background medication drive substantial dextromethorphan exposure variability.Fix one inhibitor and formulation; characterise pharmacokinetics; predefine exposure targets; perform medication reconciliation.DXM–CYP2D6NeuropsychiatricSerotonin toxicity, dissociation, sedation, agitation, psychosis, misuse potential, and mood activation.Structured mental-status monitoring; review serotonergic burden; monitor for activation and misuse; prespecify exclusion and stopping rules.DXM–CYP2D6CardiacQTc prolongation and interaction-related arrhythmia risk, particularly with quinidine-containing strategies; cardiovascular toxicity with dasatinib.ECG and electrolyte review when indicated; exclude or monitor higher-risk participants per protocol.DXM–CYP2D6; DasatinibSeizure & blood-pressureSeizure-threshold and blood-pressure effects relevant to bupropion-containing strategies and selected background medicines.Review seizure history, blood pressure, interacting drugs, and other threshold-lowering agents.DXM–CYP2D6Hematologic & bleedingMyelosuppression, thrombocytopenia, bleeding, or platelet dysfunction with oncology-drug exposure.CBC, bleeding history, medication review, and specialist oversight.DasatinibHepaticAltered clearance, organ toxicity, or accumulation; hepatotoxicity signals with dasatinib.Baseline and follow-up liver-function assessment; prespecified laboratory monitoring.Dasatinib; All armsRenalAltered clearance or accumulation of components dependent on renal elimination.Baseline and follow-up renal assessment; prespecified laboratory monitoring.All armsRespiratory & fluid retentionPleural effusion, dyspnea, pulmonary arterial hypertension, or cardiovascular toxicity with dasatinib.Specialist assessment; cardiopulmonary review; symptom-triggered evaluation; strict protocol-defined stopping rules.DasatinibPregnancy & reproductiveEmbryo-fetal toxicity and uncertain reproductive risk.Pregnancy exclusion or prevention procedures as required by protocol; specialist review.DasatinibMalignancy & immune statusUncertainty about long-term NAD modulation and senescence manipulation in active or recent malignancy.Conservative eligibility criteria; oncology review where relevant; no claim of cancer-risk protection.Dasatinib; NMN/NACProduct qualityVariable composition or contamination of non-prescription products.Standardised, analytically characterised products with batch documentation and chain-of-custody procedures.All armsCross-domain governanceAttribution of adverse events across a multi-drug regimen and staged augmentation.Adverse-event adjudication matched to the component under study; full ethics, regulatory, pharmacy, and safety oversight.All arms Table 2Translational Safety Domains and Monitoring PrioritiesSafety DomainPrincipal ConcernHigh-Level Research ResponseDextromethorphan exposureCYP2D6 phenotype, genotype, inhibitor strength, formulation, and background medication may produce substantial exposure variabilityFix one inhibitor and formulation; characterize pharmacokinetics; predefine exposure targets; perform medication reconciliationSerotonergic and neuropsychiatric effectsSerotonin toxicity, dissociation, sedation, agitation, psychosis, misuse, and mood activationStructured mental-status monitoring; review serotonergic burden; monitor for activation and misuse; define exclusion and stopping procedures prospectivelyCardiac effectsQTc prolongation and interaction-related arrhythmia risk, particularly with quinidine-containing strategiesECG and electrolyte review when indicated; exclude or monitor higher-risk participants according to protocolSeizure and blood-pressure riskRelevant to bupropion-containing strategies and selected background medicinesReview seizure history, blood pressure, interacting drugs, and other threshold-lowering agentsHematologic and bleeding effectsMyelosuppression, thrombocytopenia, bleeding, or platelet dysfunction with oncology-drug exposureCBC, bleeding history, medication review, and specialist oversightHepatic and renal effectsAltered clearance, organ toxicity, or accumulationBaseline and follow-up renal and hepatic assessment; prespecified laboratory monitoringFluid retention and pulmonary toxicityPleural effusion, dyspnea, pulmonary arterial hypertension, or cardiovascular toxicity with dasatinibSpecialist assessment; cardiopulmonary review; symptom-triggered evaluation; strict protocol-defined stopping rulesPregnancy and reproductive safetyEmbryo-fetal toxicity and uncertain reproductive riskPregnancy exclusion or prevention procedures as required by protocol; specialist reviewMalignancy and immune statusUncertainty about long-term NAD modulation and senescence manipulation in active or recent malignancyConservative eligibility criteria; oncology review where relevant; no claim of cancer-risk protectionProduct qualityVariable composition or contamination of non-prescription productsStandardized, analytically characterized products with batch documentation and chain-of-custody procedures Translational Safety Domains and Monitoring Priorities Table 3High-Level Safety-Monitoring FrameworkSafety DomainPrincipal ConcernHigh-Level Research ResponseApplies toPharmacokineticCYP2D6 phenotype, genotype, inhibitor strength, formulation, and background medication drive substantial dextromethorphan exposure variability.Fix one inhibitor and formulation; characterise pharmacokinetics; predefine exposure targets; perform medication reconciliation.DXM–CYP2D6NeuropsychiatricSerotonin toxicity, dissociation, sedation, agitation, psychosis, misuse potential, and mood activation.Structured mental-status monitoring; review serotonergic burden; monitor for activation and misuse; prespecify exclusion and stopping rules.DXM–CYP2D6CardiacQTc prolongation and interaction-related arrhythmia risk, particularly with quinidine-containing strategies; cardiovascular toxicity with dasatinib.ECG and electrolyte review when indicated; exclude or monitor higher-risk participants per protocol.DXM–CYP2D6; DasatinibSeizure & blood-pressureSeizure-threshold and blood-pressure effects relevant to bupropion-containing strategies and selected background medicines.Review seizure history, blood pressure, interacting drugs, and other threshold-lowering agents.DXM–CYP2D6Hematologic & bleedingMyelosuppression, thrombocytopenia, bleeding, or platelet dysfunction with oncology-drug exposure.CBC, bleeding history, medication review, and specialist oversight.DasatinibHepaticAltered clearance, organ toxicity, or accumulation; hepatotoxicity signals with dasatinib.Baseline and follow-up liver-function assessment; prespecified laboratory monitoring.Dasatinib; All armsRenalAltered clearance or accumulation of components dependent on renal elimination.Baseline and follow-up renal assessment; prespecified laboratory monitoring.All armsRespiratory & fluid retentionPleural effusion, dyspnea, pulmonary arterial hypertension, or cardiovascular toxicity with dasatinib.Specialist assessment; cardiopulmonary review; symptom-triggered evaluation; strict protocol-defined stopping rules.DasatinibPregnancy & reproductiveEmbryo-fetal toxicity and uncertain reproductive risk.Pregnancy exclusion or prevention procedures as required by protocol; specialist review.DasatinibMalignancy & immune statusUncertainty about long-term NAD modulation and senescence manipulation in active or recent malignancy.Conservative eligibility criteria; oncology review where relevant; no claim of cancer-risk protection.Dasatinib; NMN/NACProduct qualityVariable composition or contamination of non-prescription products.Standardised, analytically characterised products with batch documentation and chain-of-custody procedures.All armsCross-domain governanceAttribution of adverse events across a multi-drug regimen and staged augmentation.Adverse-event adjudication matched to the component under study; full ethics, regulatory, pharmacy, and safety oversight.All arms High-Level Safety-Monitoring Framework Proposed Translational Development Pathway The development sequence should be sequential rather than simultaneous. Testing the complete combination at the outset would make it difficult to identify the active component, attribute adverse events, or determine whether a biomarker changed because of the core regimen, the augmentation arm, or an unrelated treatment factor. The selected human pharmacokinetic, target-engagement, safety, and clinical studies that currently inform these considerations are summarized in Table 4. Table 4Selected Human Evidence by Component and Proposed CombinationComponent or StrategySample and PopulationComparatorDuration or Exposure WindowPrimary OutcomesAdverse Events or LimitationsSource RelationshipDextromethorphan with CYP2D6 phenotype assessment109 healthy volunteers, including extensive and poor metabolizersWithin-subject pharmacokinetic comparisonShort exposureDextromethorphan and metabolite dispositionDemonstrated major phenotype-related variability; not a psychiatric efficacy studyIndependent of current author; industry-affiliated studyDextromethorphan with quinidine inhibition1112 healthy volunteers, including extensive and poor metabolizersCrossover comparisons with and without quinidineSingle-dose pharmacokinetic studyExposure, metabolite formation, and experimental antitussive responseNot designed to evaluate depression; substantial interindividual variabilityIndependent of current authorDextromethorphan–quinidine pharmacokinetics1246 healthy extensive metabolizers in a dose-finding study and 65 in a separate pharmacokinetic studyMultiple dextromethorphan and quinidine combinationsRepeated short-term exposureExposure, accumulation, and tolerabilityIndustry-sponsored; not an antidepressant trialIndependent of current author; industry-sponsoredPiracetam during ECT3138 patients with depressive illness or schizophrenia receiving ECTPiracetam versus placeboECT course and short post-treatment periodECT-related cognitive disturbance and clinical ratingsNo significant prevention of cognitive disturbance; not a test of the proposed regimenIndependent of current authorNAC in MDD33252 adults with MDD receiving treatment as usualNAC versus placebo12-week treatment with follow-upMADRS and functional outcomesPrimary depression endpoint not significant at the prespecified endpoint; gastrointestinal and musculoskeletal adverse events were more frequent with NACIndependent of current authorNAC in depression, pooled evidence3412 randomized studies, 904 participants across depressive populationsNAC versus placebo or control8–24 weeks across studiesDepressive symptom changeHeterogeneity and wide uncertainty; not specific to TRD or the proposed regimenIndependent of current authorNMN in healthy adults3530 healthy participantsNMN versus placebo12 weeksBlood NAD-related measures and laboratory safetyNo psychiatric outcomes; healthy population and limited durationIndependent of current author; industry involvement reportedNMN in healthy middle-aged adults3680 healthy adultsPlacebo and multiple NMN groups60 daysNAD-related measures, safety, and physical or metabolic outcomesNo psychiatric outcomes; not a TRD studyIndependent of current authorNMN in healthy older men37Healthy older men; sample size reported in the original publicationNMN supplementation without psychiatric comparatorChronic supplementation periodBlood NAD-related measures and muscle functionNo psychiatric outcomes; limited generalizability to TRDIndependent of current authorDasatinib plus quercetin in diabetic kidney disease419 adults with diabetic kidney diseaseOpen-label, pre–post comparisonShort intermittent exposureSenescence-related tissue and circulating markersSmall, uncontrolled study; not psychiatricIndependent of current authorDasatinib plus quercetin in early Alzheimer’s disease425 adults with early Alzheimer’s disease who completed the pilotOpen-label, pre–post comparison12 weeksCNS penetrance, safety, feasibility, exploratory biomarkersVery small, uncontrolled study; cognitive outcomes exploratoryIndependent of current authorDasatinib plus quercetin in older adults at risk for Alzheimer’s disease4312 older adults with slow gait and mild cognitive impairmentSingle-arm pre–post study12 weeksFeasibility, cognition, mobility, and biomarkersNo appropriate control group; underpowered for efficacy; preliminary findingsIndependent of current authorProposed oral glutamatergic regimen15No participantsNoneHypothesis paperMechanistic proposal onlyNo empirical clinical dataAuthor-authored hypothesis paperProposed oral glutamatergic regimen in related populations45,46Three adults with bipolar disorder and obsessive-compulsive symptoms in one report; one longitudinal TBI bipolar-spectrum case in anotherNoneNaturalistic clinical follow-upSymptom trajectories and clinical observationsUncontrolled, confounded by concomitant treatment and outside the primary unipolar TRD target populationAuthor-authored case reportsProposed oral glutamatergic regimen plus NMN, NAC, or senotherapeutic agentNo direct human study identifiedNoneNot applicableNo direct efficacy or safety outcome availableComplete combination remains untestedNo direct evidenceNotes: “Independent of current author” indicates that the source was not authored by the present author. It does not imply absence of industry funding, intellectual-property interests, or other competing interests in the cited study.Abbreviations: CNS, central nervous system; ECT, electroconvulsive therapy; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; NAC, N-acetylcysteine; NMN, nicotinamide mononucleotide; TBI, traumatic brain injury; TRD, treatment-resistant depression. Table 4Selected Human Evidence by Component and Proposed CombinationComponent or StrategySample and PopulationComparatorDuration or Exposure WindowPrimary OutcomesAdverse Events or LimitationsSource RelationshipDextromethorphan with CYP2D6 phenotype assessment109 healthy volunteers, including extensive and poor metabolizersWithin-subject pharmacokinetic comparisonShort exposureDextromethorphan and metabolite dispositionDemonstrated major phenotype-related variability; not a psychiatric efficacy studyIndependent of current author; industry-affiliated studyDextromethorphan with quinidine inhibition1112 healthy volunteers, including extensive and poor metabolizersCrossover comparisons with and without quinidineSingle-dose pharmacokinetic studyExposure, metabolite formation, and experimental antitussive responseNot designed to evaluate depression; substantial interindividual variabilityIndependent of current authorDextromethorphan–quinidine pharmacokinetics1246 healthy extensive metabolizers in a dose-finding study and 65 in a separate pharmacokinetic studyMultiple dextromethorphan and quinidine combinationsRepeated short-term exposureExposure, accumulation, and tolerabilityIndustry-sponsored; not an antidepressant trialIndependent of current author; industry-sponsoredPiracetam during ECT3138 patients with depressive illness or schizophrenia receiving ECTPiracetam versus placeboECT course and short post-treatment periodECT-related cognitive disturbance and clinical ratingsNo significant prevention of cognitive disturbance; not a test of the proposed regimenIndependent of current authorNAC in MDD33252 adults with MDD receiving treatment as usualNAC versus placebo12-week treatment with follow-upMADRS and functional outcomesPrimary depression endpoint not significant at the prespecified endpoint; gastrointestinal and musculoskeletal adverse events were more frequent with NACIndependent of current authorNAC in depression, pooled evidence3412 randomized studies, 904 participants across depressive populationsNAC versus placebo or control8–24 weeks across studiesDepressive symptom changeHeterogeneity and wide uncertainty; not specific to TRD or the proposed regimenIndependent of current authorNMN in healthy adults3530 healthy participantsNMN versus placebo12 weeksBlood NAD-related measures and laboratory safetyNo psychiatric outcomes; healthy population and limited durationIndependent of current author; industry involvement reportedNMN in healthy middle-aged adults3680 healthy adultsPlacebo and multiple NMN groups60 daysNAD-related measures, safety, and physical or metabolic outcomesNo psychiatric outcomes; not a TRD studyIndependent of current authorNMN in healthy older men37Healthy older men; sample size reported in the original publicationNMN supplementation without psychiatric comparatorChronic supplementation periodBlood NAD-related measures and muscle functionNo psychiatric outcomes; limited generalizability to TRDIndependent of current authorDasatinib plus quercetin in diabetic kidney disease419 adults with diabetic kidney diseaseOpen-label, pre–post comparisonShort intermittent exposureSenescence-related tissue and circulating markersSmall, uncontrolled study; not psychiatricIndependent of current authorDasatinib plus quercetin in early Alzheimer’s disease425 adults with early Alzheimer’s disease who completed the pilotOpen-label, pre–post comparison12 weeksCNS penetrance, safety, feasibility, exploratory biomarkersVery small, uncontrolled study; cognitive outcomes exploratoryIndependent of current authorDasatinib plus quercetin in older adults at risk for Alzheimer’s disease4312 older adults with slow gait and mild cognitive impairmentSingle-arm pre–post study12 weeksFeasibility, cognition, mobility, and biomarkersNo appropriate control group; underpowered for efficacy; preliminary findingsIndependent of current authorProposed oral glutamatergic regimen15No participantsNoneHypothesis paperMechanistic proposal onlyNo empirical clinical dataAuthor-authored hypothesis paperProposed oral glutamatergic regimen in related populations45,46Three adults with bipolar disorder and obsessive-compulsive symptoms in one report; one longitudinal TBI bipolar-spectrum case in anotherNoneNaturalistic clinical follow-upSymptom trajectories and clinical observationsUncontrolled, confounded by concomitant treatment and outside the primary unipolar TRD target populationAuthor-authored case reportsProposed oral glutamatergic regimen plus NMN, NAC, or senotherapeutic agentNo direct human study identifiedNoneNot applicableNo direct efficacy or safety outcome availableComplete combination remains untestedNo direct evidenceNotes: “Independent of current author” indicates that the source was not authored by the present author. It does not imply absence of industry funding, intellectual-property interests, or other competing interests in the cited study.Abbreviations: CNS, central nervous system; ECT, electroconvulsive therapy; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; NAC, N-acetylcysteine; NMN, nicotinamide mononucleotide; TBI, traumatic brain injury; TRD, treatment-resistant depression. Selected Human Evidence by Component and Proposed Combination Notes: “Independent of current author” indicates that the source was not authored by the present author. It does not imply absence of industry funding, intellectual-property interests, or other competing interests in the cited study. Abbreviations: CNS, central nervous system; ECT, electroconvulsive therapy; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; NAC, N-acetylcysteine; NMN, nicotinamide mononucleotide; TBI, traumatic brain injury; TRD, treatment-resistant depression. Stage 1: Characterize One Fixed Oral Glutamatergic Regimen The first study should select one CYP2D6 inhibitor and one formulation and characterize the pharmacokinetics, exposure variability, tolerability, interaction profile, and preliminary clinical signal of the dextromethorphan–CYP2D6-inhibitor–piracetam regimen. The core regimen should be evaluated before adding NMN, NAC, glutamine, or any senescence-directed agent. A small study of approximately 20–30 participants could be suitable for feasibility, common tolerability, adherence, pharmacokinetic characterization, and preliminary target engagement. It would not be capable of establishing antidepressant efficacy, durability, or uncommon toxicities. If participants with TRD are included, the study should use a clearly defined unipolar population and stabilize background treatment before exposure assessment. Stage 2: Test NMN Plus NAC Augmentation Only after the core regimen has been characterized should NMN plus NAC be evaluated. This stage should determine whether the augmentation produces prespecified changes in NAD-related measures, redox markers, inflammatory markers, or other target-engagement outcomes. Clinical outcomes should remain secondary until the biological and safety signals are interpretable. Potential clinical measures include MADRS or QIDS scores, fatigue, sleep, cognitive performance, functional recovery, and adverse-event burden. Biomarkers could include NAD metabolite profiles, CRP, selected cytokines, GSH/GSSG, CBC, renal and hepatic function, and a predefined SASP panel. Peripheral biomarker changes should not be interpreted as evidence of central synaptic repair without additional validation. Stage 3: Consider a Senescence-Directed Component A senotherapeutic arm should be considered only if the prior stages demonstrate acceptable safety, adherence, and target engagement. A lower-risk, standardized, non-oncology candidate could be considered before dasatinib-containing strategies. The development plan should include a prespecified biomarker rationale and should not proceed solely on the basis of symptom improvement in an uncontrolled pilot. Dasatinib plus quercetin should be reserved for a later and more restrictive study, if considered at all. Its use would require specialist oversight and a monitoring framework appropriate for an oncology drug. The absence of a psychiatric efficacy signal from lower-risk candidates should not automatically justify progression to dasatinib. Controlled Study Design A controlled augmentation trial should separate core-regimen effects from augmentation effects. A design in which every participant receives the core regimen can evaluate the incremental effect of the augmentation but cannot establish the efficacy or safety of the core regimen itself. The core regimen must therefore be characterized in an earlier study or included in a design with an appropriate comparator. After core characterization, a possible augmentation design could compare: Fixed oral glutamatergic regimen plus placebo augmentation;Fixed oral glutamatergic regimen plus NMN and NAC;Fixed oral glutamatergic regimen plus NMN, NAC, and a prespecified candidate senescence-directed intervention; andA comparator condition that does not receive the fixed oral glutamatergic regimen, if ethically and scientifically justified. Fixed oral glutamatergic regimen plus placebo augmentation; Fixed oral glutamatergic regimen plus placebo augmentation; Fixed oral glutamatergic regimen plus NMN and NAC; Fixed oral glutamatergic regimen plus NMN and NAC; Fixed oral glutamatergic regimen plus NMN, NAC, and a prespecified candidate senescence-directed intervention; and Fixed oral glutamatergic regimen plus NMN, NAC, and a prespecified candidate senescence-directed intervention; and A comparator condition that does not receive the fixed oral glutamatergic regimen, if ethically and scientifically justified. A comparator condition that does not receive the fixed oral glutamatergic regimen, if ethically and scientifically justified. The exact design would depend on safety information, regulatory advice, background treatment, and the ability to maintain blinding. The statistical analysis should prespecify the primary endpoint, biomarker hierarchy, multiplicity-control strategy, subgroup interaction tests, missing-data approach, and follow-up duration. A small pilot should not be used to justify an efficacy claim or to estimate uncommon safety events. Go/no-go criteria should be established before enrollment. Development should narrow or stop if the selected inhibitor fails to produce interpretable pharmacokinetic exposure, if adverse events prevent adherence, if target biomarkers are not engaged, if product quality cannot be standardized, or if clinical signals are unrelated to the proposed mechanistic pathway. Progression should require acceptable safety, interpretable target engagement, reproducible clinical measurement, and evidence that any signal is enriched in the prespecified biological subgroup. Alternative Explanations and Falsifiability Several alternative explanations could account for apparent improvement in uncontrolled observations. These include the intrinsic antidepressant activity of bupropion, fluoxetine, paroxetine, or another CYP2D6 inhibitor; expectancy effects; regression to the mean; spontaneous fluctuation in depressive symptoms; changes in sleep or activity; concomitant treatment adjustments; selective reporting; and the therapeutic relationship. The contribution of dextromethorphan, piracetam, NAC, NMN, or a senescence-directed agent cannot be inferred from a naturalistic response sequence. The proposed framework makes several falsifiable predictions: If a fixed CYP2D6 inhibitor does not produce a reproducible and clinically relevant dextromethorphan exposure profile, the pharmacokinetic basis of the regimen would require reformulation.If pharmacokinetic target engagement occurs but does not produce evidence of downstream pharmacodynamic activity, the assumed link between exposure and plasticity initiation would be weakened.If piracetam adds no reproducible pharmacodynamic, functional, or clinical signal in a controlled study, the proposed NMDA-to-AMPA sequence would require revision.If NMN changes NAD-related measures but does not alter prespecified redox, bioenergetic, inflammatory, or durability outcomes, its proposed role as a consolidation intervention would be unsupported.If NAC changes peripheral redox or glutamate-related markers without improving response durability, the assumption that redox stabilization is a limiting factor would be weakened.If baseline senescence, inflammatory, or bioenergetic markers do not enrich response or durability, the proposed biomarker-defined subgroup strategy would require reformulation.If a senescence-directed agent changes peripheral SASP markers but fails to show a consistent relationship with clinical or central measures, the assumption that peripheral senescence reduction reflects meaningful brain plasticity support would be challenged.If the combination produces unacceptable adverse events, poor adherence, or clinically significant interaction burden, the translational strategy would not be justified even if a preliminary symptom signal were observed. If a fixed CYP2D6 inhibitor does not produce a reproducible and clinically relevant dextromethorphan exposure profile, the pharmacokinetic basis of the regimen would require reformulation. If a fixed CYP2D6 inhibitor does not produce a reproducible and clinically relevant dextromethorphan exposure profile, the pharmacokinetic basis of the regimen would require reformulation. If pharmacokinetic target engagement occurs but does not produce evidence of downstream pharmacodynamic activity, the assumed link between exposure and plasticity initiation would be weakened. If pharmacokinetic target engagement occurs but does not produce evidence of downstream pharmacodynamic activity, the assumed link between exposure and plasticity initiation would be weakened. If piracetam adds no reproducible pharmacodynamic, functional, or clinical signal in a controlled study, the proposed NMDA-to-AMPA sequence would require revision. If piracetam adds no reproducible pharmacodynamic, functional, or clinical signal in a controlled study, the proposed NMDA-to-AMPA sequence would require revision. If NMN changes NAD-related measures but does not alter prespecified redox, bioenergetic, inflammatory, or durability outcomes, its proposed role as a consolidation intervention would be unsupported. If NMN changes NAD-related measures but does not alter prespecified redox, bioenergetic, inflammatory, or durability outcomes, its proposed role as a consolidation intervention would be unsupported. If NAC changes peripheral redox or glutamate-related markers without improving response durability, the assumption that redox stabilization is a limiting factor would be weakened. If NAC changes peripheral redox or glutamate-related markers without improving response durability, the assumption that redox stabilization is a limiting factor would be weakened. If baseline senescence, inflammatory, or bioenergetic markers do not enrich response or durability, the proposed biomarker-defined subgroup strategy would require reformulation. If baseline senescence, inflammatory, or bioenergetic markers do not enrich response or durability, the proposed biomarker-defined subgroup strategy would require reformulation. If a senescence-directed agent changes peripheral SASP markers but fails to show a consistent relationship with clinical or central measures, the assumption that peripheral senescence reduction reflects meaningful brain plasticity support would be challenged. If a senescence-directed agent changes peripheral SASP markers but fails to show a consistent relationship with clinical or central measures, the assumption that peripheral senescence reduction reflects meaningful brain plasticity support would be challenged. If the combination produces unacceptable adverse events, poor adherence, or clinically significant interaction burden, the translational strategy would not be justified even if a preliminary symptom signal were observed. If the combination produces unacceptable adverse events, poor adherence, or clinically significant interaction burden, the translational strategy would not be justified even if a preliminary symptom signal were observed. These criteria are intended to keep the proposal testable A negative result would not necessarily disprove the broader relationship among glutamatergic plasticity, aging biology, inflammation, and treatment resistance, but it would constrain the specific pharmacological model. Relationship to the Author’s Prior Work The prior author-authored hypothesis paper proposed a four-component oral strategy involving dextromethorphan, CYP2D6 inhibition, piracetam, and glutamine.15 Subsequent preprints developed pruning–plasticity, network-consolidation, and symptom-level bioenergetic models.28–30 Related case reports described uncontrolled observations in bipolar-spectrum and post-traumatic brain injury populations.45,46 The present paper differs in four respects: it removes the eponymous label; defines a reproducible core regimen without glutamine; separates the core regimen from the NMN-plus-NAC augmentation arm; and places senescence-directed treatment behind sequential pharmacokinetic, safety, and target-engagement gates. The current paper also shifts the principal outcome from an assumed rapid antidepressant response to a testable question about response durability. It does not claim that the author’s prior observations establish efficacy, does not treat the author’s preprints as confirmatory evidence, and does not assign a clinical role to the proposed combinations. The relationship between the present article and the author’s related publications is summarized in Table 5. Table 5Scope Relative to Related Author-Authored PublicationsPublication or SourceMain ContributionPopulation or Evidence TypeLimitation Relative to the Present FrameworkCheung 2026 oral glutamatergic hypothesis paper15Proposed dextromethorphan, CYP2D6 inhibition, piracetam, and glutamine as a mechanistic oral strategyHypothesis and theoryDid not test the complete regimen clinically; included a broader and more prescriptive compositionCheung pruning–plasticity model28Proposed a genetic and developmental framework linking pruning and adult plasticityPreprint-based genetic and causal inferenceHypothesis-generating; not a clinical treatment studyCheung network-fragility simulation29Modeled vulnerability, reconnection, and recovery after simulated pruningComputational modelDoes not establish biological or clinical efficacyCheung symptom-level bioenergetic model30Linked fatigue, NAD-related biology, mitochondria, and antidepressant outcomesPreprint-based transcriptomic and mechanistic analysisBiomarker and treatment-response relationships require independent replicationCheung bipolar/OCD case series45Described three consecutive routine-practice casesUncontrolled case series; bipolar/OCD populationNot unipolar TRD; no randomized comparator; confounding by background treatmentCheung TBI bipolar-spectrum case46Described longitudinal treatment observations after TBISingle uncontrolled case reportNot unipolar TRD; cannot establish efficacy or generalizabilityPresent frameworkSeparates the core regimen from NMN-plus-NAC augmentation, removes eponymous naming, maps human evidence, and proposes sequential testingTranslational hypothesis paper; no original dataRequires prospective pharmacokinetic, safety, efficacy, and independent replication studies Table 5Scope Relative to Related Author-Authored PublicationsPublication or SourceMain ContributionPopulation or Evidence TypeLimitation Relative to the Present FrameworkCheung 2026 oral glutamatergic hypothesis paper15Proposed dextromethorphan, CYP2D6 inhibition, piracetam, and glutamine as a mechanistic oral strategyHypothesis and theoryDid not test the complete regimen clinically; included a broader and more prescriptive compositionCheung pruning–plasticity model28Proposed a genetic and developmental framework linking pruning and adult plasticityPreprint-based genetic and causal inferenceHypothesis-generating; not a clinical treatment studyCheung network-fragility simulation29Modeled vulnerability, reconnection, and recovery after simulated pruningComputational modelDoes not establish biological or clinical efficacyCheung symptom-level bioenergetic model30Linked fatigue, NAD-related biology, mitochondria, and antidepressant outcomesPreprint-based transcriptomic and mechanistic analysisBiomarker and treatment-response relationships require independent replicationCheung bipolar/OCD case series45Described three consecutive routine-practice casesUncontrolled case series; bipolar/OCD populationNot unipolar TRD; no randomized comparator; confounding by background treatmentCheung TBI bipolar-spectrum case46Described longitudinal treatment observations after TBISingle uncontrolled case reportNot unipolar TRD; cannot establish efficacy or generalizabilityPresent frameworkSeparates the core regimen from NMN-plus-NAC augmentation, removes eponymous naming, maps human evidence, and proposes sequential testingTranslational hypothesis paper; no original dataRequires prospective pharmacokinetic, safety, efficacy, and independent replication studies Scope Relative to Related Author-Authored Publications Conclusion This proposal is best understood as a candidate investigational framework for studying whether glutamatergic plasticity initiation and senescence-, redox-, or bioenergetic modulation interact in a biologically enriched subset of unipolar treatment-resistant depression. The oral dextromethorphan–CYP2D6-inhibitor–piracetam regimen remains pharmacokinetically and clinically unvalidated. NMN is a candidate NAD-related target-engagement intervention, not an established antidepressant. NAC has heterogeneous adjunctive psychiatric evidence but no regimen-specific efficacy evidence. Senotherapeutic agents remain experimental, and dasatinib plus quercetin has a safety profile that makes it unsuitable for routine psychiatric augmentation. No clinical role can yet be assigned to any proposed combination. The appropriate next steps are sequential pharmacokinetic characterization, Phase I safety and feasibility studies, biomarker validation, controlled augmentation trials, at least 6–12 months of follow-up for durability outcomes, and independent replication. None of the combinations should be used outside formal research protocols.